BCAL Diagnostics Limited (AU:BDX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BCAL Diagnostics Limited is gearing up for the commercial launch of their breast cancer detection tool, BREASTEST®, with a new commercial license agreement with Sydney Breast Clinic. The company has also started operations in the US, establishing a subsidiary and securing research facilities, while continuing to enhance its intellectual property portfolio with patents and trademarks. With a cash reserve of $7.1 million and additional funds from R&D tax offsets, BCAL is poised for significant growth and market entry.
For further insights into AU:BDX stock, check out TipRanks’ Stock Analysis page.